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Figure 1- Replikin CountTM Increases in H1N1 and H5N1 Globally and Locally 
        Annual Mean Replikin CountsTM, blue; Standard Deviation of the Mean (SD), red    
Predictions:    H1N1 Sixth and Seventh Predictions (3,10)        H5N1  Fifth Prediction (4)                     
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Legend for Figure 1: Note for H1N1 the gradual increase in the annual mean Replikin CountTM 
globally; and in contrast, the approximately 40% increase in the H1N1 Count in Mexico between 
2008 and 2009 which preceded the selective H1N1 outbreak in Mexico in 2009 and the pandemic. 
Similarly, note the gradual increase in the global mean H5N1 Counts and the marked increase in 
the H5N1 p B1 Count in Cambodia in 2009 (pB1-F2 frame Count alone increased from 17.8 to 
28.9, not shown) which was followed by the unique outbreaks in Cambodia in 2011 and 2012 
(now also being reported in neighboring Vietnam). The size of the SD (in red) indicates the 
proportion of viruses in a given population with high Replikin CountsTM (previously associated 
with rapid replication (1,12)) and the diversity of the Replikin CountsTM (number of Replikins per 
100 amino acids) in the genomes of a virus population (1). In Figure 1, there is a greater 
proportion of the H5N1 virus population than that of H1N1 engaged in rapid replication. During 
low rate of replication ‘rest periods’ and small values of the mean Count (in blue), the SD (in red) 
is small or zero, as also observed with influenza B over many decades (1); during periods of rapid 
replication, the SD is larger in relation to the mean. Global Counts are those for all countries 
combined; Counts for Mexico and Cambodia are those in each country respectively.  
 
Summary 
 
Earlier studies have shown that the increased concentration of a new class of 
virus genomic peptides, Replikins, precedes and predicts virus outbreaks (1). We 
now find that the area in the genome of the highest concentration of Replikins, 
and the country in which this peak exists in scout viruses, have permitted in the 
past five years seven consecutive accurate predictions of the geographic 
localization of coming outbreaks, including those now realized in Mexico for 
H1N1, and in Cambodia for H5N1. Real-time Replikin analysis of the evolution 
of the virus genome identified both mutations and structural reorganization of the 
hemagglutinin and p B1 genes over several years before each outbreak. This 
information, together with the specific Replikin sequences so obtained, permitted 
solid-phase synthesis of Replikin vaccines in seven days, which blocked H5N1 in 
chickens (13). The information also now provides up to two years of time to 
thoroughly test and distribute vaccines to high risk individuals in the countries 
identified; thus for the first time, a quantitative genomic Replikins method to both 
predict initial outbreaks and to prevent the development of a pandemic. 
 
Methods  
 
Software based on the authors’ algorithm (9) first identified and then counted the replikin peptides 
in each genomic sequence (Replikin CountTM = number of replikins per 100 amino acids). For 
each annual group of sequences, the Replikin CountTM mean and standard deviation of the mean 
(SD) were calculated and compared with other years. Highly statistically significant increases and 
decreases were examined, for example by strain, host, country, history, year, month or week; by 
substitution, morbidity, and lethality. The terms ‘increase’ and ‘decrease’ of Replikin CountsTM 
were used only when the p level was less than 0.001. All Counts for H1N1, H5N1 and other 
influenza strains were each monitored separately, retrospectively and prospectively, from 2003 to 
2011 for all countries reporting to Pubmed.  Replikin CountsTM were compared to Counts for the 
same strain in outbreak and non-outbreak (‘resting’) time periods. Statistical analyses of rate of 
change, trend, pattern, and growth models in the evolution of each virus strain were initiated. 
Replikin genes were isolated in silico by scanning and identifying those areas of the virus genome 
which had the highest concentration of replikins. The Count in a given strain was compared with 
the Count in other strains, and between countries in the same year, and these results compared 
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with the occurrence of outbreaks, to determine if Count increases could be advance predictive 
markers of outbreaks of the strain and in the country which were host to those highest Counts 
(Figure 1). When the eight H5N1 genomic areas were examined year by year, gene areas were 
found which became upregulated when associated with particular outbreaks. When the 
upregulation was found to be associated with high infectivity (morbidity over time period), the 
high Count area was named Replikin Infectivity Gene. When a high Count area in a sequence was 
found to be associated with high mortality rates, the high Count area was named Replikin 
Lethality Gene. The Replikin CountTM of these two genes in the H1N1 virus were determined 
annually from 2001 to 2008 before the pandemic, then during the pandemic ‘real-time’ every few 
days, then weekly, from April 2009 to February 2011 (1). Replikin peptides were visualized by 
two means: a) by linear display of sequences of contiguous numbered amino acids in the primary 
structure and b) by X-ray diffraction analysis of the 3-dimensional folded structure, which showed 
the increased coverage by Replikins of the HA gene surface in H1N1 real-time as the Replikin 
CountTM increased from 3.2 to 5.5 to 10.1 from before to during the course of the pandemic of 
2009 (1).  
 
Results 
 
Statistical Analysis of Replikin CountTM Changes  
 
The terms ‘increase’ and ‘decrease’ of Replikin CountsTM were used only when 
the p level for the change was less than 0.001. Additional independent statistical 
analysis by Associate Professor of Biostatistics Todd MacKenzie, PhD, 
Dartmouth Medical School showed, for example, that the increase in mean counts 
for H1N1 globally between 2008 and 2009 of 3.1 (95% Conf. Int. 2.9 to 3.3) was 
a statistically significant increase: p-value (t-test)=1/10130, p-value (Wilcoxon 
rank sum)<1/1016 (1). 
 
First Five Predictions 
 
Figure 1 shows that while the high-lethality H5N1 p B1 gene Replikins CountTM 
increased gradually globally from 2001 to 2010, uniquely in Cambodia the Count 
increased markedly in 2009 (Figure 1).  Lethal H5N1 outbreaks occurred in 
Cambodia in 2011 and continue into 2012. This is the fifth instance in which the 
specific strain and specific location of an influenza outbreak was predicted by the 
Replikins CountTM (number of genomic Replikin peptides per 100 amino acids) 
alone, one to two years in advance of the outbreak, together with the country in 
which the outbreak would occur.  The previous four predictions were made for 
H5N1 in Indonesia in 2006 (11), for H1N1 in Mexico in 2008, which spread to 
become the global pandemic of 2009 (1), for H1N1 in Europe in 2010 (1), and for 
H1N1 in Mexico in 2010 for the outbreak there in 2011 (3,8,14). The current 
Replikins CountTM in Cambodia has not yet decreased, as it does when the 
outbreaks are over (1). Replikins CountTM warning may enable the prevention of 
emerging diseases rather than just waiting passively for the outbreak.  
 
Sixth and Seventh Predictions 
 
After the prediction in 2008 of the H1N1 pandemic of 2009 (1,3,7,10), the 
prediction of the sixth outbreak, again of H1N1 in Mexico, was made in April 
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2010 (4), (see Figure 1). This prediction was followed by outbreaks in Chihuahua, 
Mexico in the spring of 2011 (5). Because of the persistent rise in the Replikin 
CountTM to its highest level in 50 years, the seventh prediction of outbreaks, made 
in April 2010 (4), again in Mexico, was repeated in August, 2011 (14), and the 
outbreak was realized in February 2012. The State Health Secretary in Oaxaca, 
Mexico announced on February 18, 2012 the occurrence of 262 cases of H1N1 
influenza with 12 deaths (6). This represents the seventh instance where, for a 
specific influenza strain, both the outbreak and the country in which the outbreak 
would occur were predicted by the highest viral genomic Replikin CountTM alone.  
Discussion 
These are the first accurate predictions of virus outbreaks (1), and now prediction 
of their location, based on virus genomic changes. The accuracy of Replikin 
CountTM predictions, acknowledged by the UN FAO (3) and greenlighted by the 
UK Department of Trade and Investment (16), provides for the first time up to 
two years of time to respond to specific viral genomic Replikin structures which 
are in the evolutionary process of preparing for a coming outbreak. The years of 
mutations and molecular reorganization of genomic Replikins which precede an 
outbreak, were demonstrated by X-ray diffraction (1). X-ray diffraction analysis 
of the 3-dimensional folded structure, has shown the increased coverage by 
Replikins of the HA gene surface in H1N1 real-time as the Replikin CountTM 
increased from 3.2 to 5.5 to 10.1 over the years during the development and 
course of the pandemic of 2009 (1). The time taken for these changes to occur, 
encourages the consideration that prevention of a pandemic is possible for the 
first time. In contrast, the exact Replikin sequences revealed make it possible to 
produce in as few as 7 days an effective vaccine for the most recent mutations 
(13). 
If the 2009 H5N1 sequences had been published for example on Pubmed making 
them available for Replikins analysis in 2009, instead of their apparently first 
publication in 2011, it would have provided a two-year advance warning of the 
high mortality human outbreaks now occurring in Cambodia in 2011-2012 (8,15).  
Two years would have been available to prepare, to test, to distribute, and to 
administer to high-risk individuals in Cambodia specific Replikins 
TransFluTMVaccine or other vaccines. Now that it is recognized by the UN FAO 
(3) that the Count provides a reliable predictive marker of outbreaks, and seven 
successive correct predictions have been made in the past five years, genomic 
sequence analysis should be made available as soon as possible for earliest 
possible Replikins CountTM Analysis.  
 
The Replikins CountTM is the first quantitative genomic method to predict 
outbreaks of influenza and other lethal infectious diseases, and thus a quantitative 
genomic key to explore, track, and predict virus and bacterial evolution. Since 
1917, influenza outbreaks invariably follow or accompany marked increases in 
the Count; and disappearance of the outbreak occurs with decrease in the Count 
(1). The current data demonstrates that the evolution of a particular strain of 
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influenza virus, although often gradual over years, with time for host defense 
adaptation, as for H1N1 in Mexico 2003-2008 (Figure 1), can be rapid, with more 
immediate disease consequences, as in Indonesia in 2006 (11), and in Cambodia 
in 2009 for the current outbreak (Figure 1).  
 
A book in preparation, The Evolution of Lethal Replikins (12), will provide a 
fuller report of the evolutionary development of lethal Replikins pathogens in 
influenza, in other viruses, bacteria and trypanosomes.  It will also more fully 
discuss the role of the Replikins CountTM as a marker of and determinant of 
lethality. 
In 2008, the increasing Replikin CountTM predicted the H1N1 Pandemic of 2009 
(3,10). Pharmaceutical companies began their response only when the outbreaks 
began in 2009, and because of the limitations of the old biological vaccine 
production methods used, were able to deliver their vaccine to only 20% of those 
needing it, eight months after the outbreak.  Too little, too late.   
 
In 2010-2011, this new Replikins technology again has accurately predicted 
strain-specific and location-specific outbreaks and thus has made possible the 
production, testing, and delivery of an updated Replikins vaccine which reflects 
the most recent Replikin mutations that have occured, - in advance of the next 
outbreak. Replikins	  Solid-­‐Phase	  Synthetic	  Vaccines	  can	  now	  be	  	  further	  tested	  to	  determine	  if	  they	  will	  offer	  the	  following	  advantages,	  as	  was	  evident	  in	  the	  first	  trial	  (13):	   1. Key	   Epitopes:	   The	   vaccine	   is	   based	   on	   parts	   of	   the	   influenza	   virus	  proven	  to	  be	  key	  to	  clinical	  outbreaks	  since	  1918,	  and	  specifically,	  the	  current	  vaccine	  for	  both	  H1N1	  and	  H5N1	  is	  updated	  so	  that	  it	  is	  based	  on	  genomic	  Replikins	  increasing	  for	  the	  coming	  outbreaks;	  2. Time	  to	  outbreak:	  The	  advance	  notice	  of	  coming	  outbreaks,	  based	  on	  Replikin	   CountTM,	   gives	   up	   to	   two	   years	   before	   the	   outbreak	   to	  prepare,	   test	   and	   distribute	   the	   vaccine;	   other	   vaccines	   based	   on	  biological	   methods,	   will	   require	   four	   to	   eight	   months	   after	   the	  outbreak	  to	  be	  delivered	  to	  the	  population	  at	  risk;	  3. Time	   to	   produce:	   The	   vaccine	   is	   a	   completely	   solid-­‐phase	   synthetic	  product	  which	  has	  been	  manufactured	  in	  7	  days;	  4. No	  refrigeration	  required:	  The	  vaccine	  is	  delivered	  freeze-­‐dried.	  5. Quantity:	   The	   vaccine	   can	   be	   made	   in	   unlimited	   amounts,	   and	   at	  lower	   costs,	   for	   the	   7	   billion	   humans	   and	   more	   animals;	   other	  vaccines	   have	   been	   limited	   to	   approximately	   1.25	   billion	   doses	  delivered	  8	  months	  after	  the	  outbreak,	  as	  in	  2009;	  6. Side	   effects:	   No	   known	   undesirable	   contaminants.	   The	   solid-­‐phase	  synthetic	   vaccine	   contains	   no	  DNA,	   as	   proposed	   for	   other	   vaccines)	  which	   if	   incorporated	   into	   the	   human	   genome,	   can	   have	   unknown	  generational	   effects	   in	   perpetuity	   (a	   potentially	   very	   ‘long-­‐acting’	  medication).	   It	   contains	   no	   contaminating	   biological	   substances	  (because	  throughout	  manufacture	  and	  delivery	  the	  vaccine	  never	  is	  in	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contact	   with	   any)	   with	   potential	   side	   effects	   such	   as	   Guillain-­‐Barre	  Syndrome.	   	   For	   example,	   Replikins	   vaccine	   contain	   only	   peptides,	  which	  have	  a	  short	  half-­‐life	  and	  a	  long	  safe	  history	  of	  therapeutic	  use.	  	  
Conclusion	  Replikins	  predictive	  technology	  makes	  possible	  a	  practical,	  relatively	  inexpensive,	  country-­‐specified	  method	  to	  undertake	  the	  prevention	  of	  pandemics.	   
References 
 
1.  Bogoch, Samuel and Bogoch, Elenore. Prediction of specific virus outbreaks 
made from the increased concentration of a new class of virus genomic peptides, 
replikins. Nature Precedings <http://dx.doi.org/10.1038/npre.2011.6279.1> 
(2011) 
 
2. Bogoch, Samuel and Bogoch, Elenore.	   Marked Rise in Replikin Counts in 
H5N1 Influenza Virus Localized to Lethality Gene p B1.Nature Precedings 
<http://dx.doi.org/10.1038/npre.2011.6420.1>(2011)  
 
3. UN Food and Agriculture Organization (FAO) discussion of Replikins, DVM 
Newsmagazine, (Sept. 8, 2011).  Reproduced in Report #42 , Replikins.com. 
 
4. Report #36. Replikins.com. Both H5N1 Bird Flu and H1N1 Swine Flu Replikin 
Counts™ Increasing. (April 9, 2010). 
5. Cordova, JA. Minister of Health, Mexico. Chihuahua outbreak H1N1.Xinhua 
English News.cn. China. (April 8, 2011).  
6. Germán Tenorio Vasconcelos, State Health Secretary. H1N1 Influenza in 
Oaxaca, Mexico. Via Milenio.com. (February 18, 2012).   
7. Report #18. Replikins.com. H1N1 Influenza Virus with Highest Replikin 
Count™ Since the 1918 Pandemic Identified in the U.S. and Austria (April 7, 
2008).  	  8.	   Associated	   Press.	   Vietnam	   and	   Cambodia	   Report	   Bird	   Flu	   Deaths.	   Wall	  Street	  Journal,	  page	  1,	  (January	  20,	  2012).	  	  	  9.	  	  ‘Bogoch	  Software’:	  	  FluForecastTM	  	  and	  Bioradar	  TM	  from	  Replikins,	  Ltd.,	  London	  Bioscience	  Innovation	  Centre,	  2	  Royal	  College	  Street,	  	  London	  NW1	  0NH,	  	  United	  Kingdom.	  
 
10. Report #26. Replikins.com. Replikins Provided Advance Warning of Mexican 
H1N1 "Swine Flu" Virus Outbreak (April 25, 2009). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.6
95
2.
1 
: P
os
te
d 
1 
M
ar
 2
01
2
	   7	  
 
11. Report #12, Replikins.com. Indonesia Reports Experiencing Human H5N1 
Mortality Increase, as Predicted Last Year by Replikins' FluForecast® 
Quantitative Virus Analysis (June 8, 2007).  
 
12. Bogoch S and Bogoch ES. The Evolution of Lethal Replikins. In preparation, 
2012.	  	  	  13.	   Jackwood,	  MW	   et	   al.	  Efficacy	   of	   a	  Replikin	   peptide	  Vaccine	  Against	   Low	  
Pathogenicity	  Avian	  Influenza	  H5	  Virus.	  Avian	  Diseases	  53(4):613-­‐617,	  2009.	  	  14.	  Report	  #41. Replikins.com.	  FAO	  Warnings	  Follow	  Rise	   in	  Replikins	  Count	  
for	  both	  H5N1	  and	  H1N1.	  (August	  31,	  2011).	  
 
15.Report #45. Replikins.com. Current H5N1 Flu Outbreak and Location 
Predicted in 2009. (February 10, 2012). 
16.Report	   #35. Replikins.com. Flu Pandemic Warning Company sets up in UK 
(March 25, 2010).  
    
 
  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.6
95
2.
1 
: P
os
te
d 
1 
M
ar
 2
01
2
	   8	  
 
	  
                                                                         
 	  
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.6
95
2.
1 
: P
os
te
d 
1 
M
ar
 2
01
2
